OrthoPediatrics is the only pure-play pediatric orthopedic implant company in the world, and its second quarter of 2026 shows a business whose top line is finally outrunning its cost base. The central debate is whether a company with triple-digit gross margins and double-digit revenue growth can convert that momentum into sustained positive free cash flow before its expensive debt obligations force its hand.
The most important recent development is the acceleration in trauma and deformity, the category that generates most of the company's revenue. The second quarter print shows that category growing in the mid-twenties percent range year over year, driven by the limited launch of the 3P Hip plating system and the full rollout of the Pediatric Nailing Platform for the tibia. That acceleration arrived while scoliosis, the company's second category, declined in the same quarter, signaling a product mix shift rather than a broad-based volume recovery.
The tension sits in the balance sheet. The company holds roughly $48 million in cash and short-term investments against $100 million of Braidwell debt, split between a term loan and a tranche of convertible notes. Interest expense alone absorbed a meaningful portion of operating income in the second quarter. The March 2026 amendment that added a delayed draw term loan extended the runway but also deepened the leverage. The balance sheet is the binding constraint on the growth story.
The catalyst is the 3P Small and Mini launch and the first full year of Boston O&P clinic economics. The question is whether the product cycle is a step function or a one-time pop. If trauma growth holds in the high teens or above and the O&P network stabilizes, the operating loss narrows fast enough to matter.